Trending

European Commission

Division on European HTA

Division on European HTA

There have been aspirations for closer collaboration between European Union (EU) Member States (MS) on Health Technology Assessment

X

Division on European HTA

https://pharmaphorum.com/views-and-analysis/hta-european-health-technology-assessment-division-progress/

Pfizer wins Herceptin biosimilar approval in Europe

Pfizer wins Herceptin biosimilar approval in Europe

European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first

X

Pfizer wins Herceptin biosimilar approval in Europe

https://pharmaphorum.com/news/herceptin-biosimilar-european-approval/

Who should pay for HTA?

Who should pay for HTA?

Part of the drive for strengthening EU cooperation on health technology assessment (HTA) is to tackle duplication of

X

Who should pay for HTA?

https://pharmaphorum.com/views-analysis-digital/who-should-pay-hta/

European Commission ploughs €100 billion into new R&D programme

European Commission ploughs €100 billion into new R&D programme

The European Commission has dedicated €100 billion to its new Horizon Europe programme to fund research and innovation.

X

European Commission ploughs €100 billion into new R&D programme

https://pharmaphorum.com/news/european-commission-rd-programme/

EC to update IP rules to benefit generic exports

EC to update IP rules to benefit generic exports

The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.

X

EC to update IP rules to benefit generic exports

https://pharmaphorum.com/news/ec-update-ip-rules-generic-exports/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com